



Aadi Bioscience to Report Second Quarter 2024 Results and Corporate Update

July 31, 2024

Company to Host Conference Call and Webcast on August 7, 2024

LOS ANGELES, July 31, 2024 /PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ: AADI), a commercial-stage precision oncology company focused on developing and commercializing therapies for cancers with alterations in the mTOR pathway, today announced that it will host a conference call and live webcast on Wednesday, August 7, 2024, at 8:30 am EDT (5:30 am PDT) to report second quarter 2024 financial results and provide recent corporate updates.

Conference Call Information

Participants may access a live webcast of the call on the "Investors & News" page of the Aadi Bioscience website at aadibio.com. To participate via telephone, please register in advance here: [Conference Registration \(vevent.com\)](http://vevent.com). Upon registration, all telephone participants will receive a confirmation email detailing how to join the conference call, including the dial-in number along with a unique passcode and registrant ID that can be used to access the call. A replay of the conference call and webcast will be archived on the website for at least 30 days.

About Aadi Bioscience, Inc.

Aadi is a commercial-stage precision oncology company focused on the development and commercialization of therapies for cancers with alterations in the mTOR pathway, a key regulator of cell growth and cancer progression. To unlock the full potential of mTOR inhibition, Aadi uniquely combines nanoparticle albumin-bound (*nab*) technology with the potent mTOR inhibitor, sirolimus. Aadi received FDA approval and commercializes FYARRO® for the treatment of adult patients with locally advanced unresectable or metastatic malignant perivascular epithelioid cell tumor (PEComa).

Aadi is exploring *nab*-sirolimus in PRECISION1, a Phase 2 tumor-agnostic registration-intended trial in mTOR inhibitor-naïve malignant solid tumors harboring *TSC1* or *TSC2* inactivating alterations. Aadi is also exploring *nab*-sirolimus in two single-indication Phase 2 trials for difficult-to-treat mTOR-driven cancers: neuroendocrine tumors (NETs) of the lung, gastrointestinal tract and pancreas, and advanced or recurrent endometrioid-type endometrial cancer (EEC) in combination with letrozole. More information on Aadi's development pipeline is available on the Aadi website at www.aadibio.com and connect with us on Twitter and LinkedIn.

Contact:

IR@aadibio.com



View original content to download multimedia: <https://www.prnewswire.com/news-releases/aadi-bioscience-to-report-second-quarter-2024-results-and-corporate-update-302211486.html>

SOURCE Aadi Bioscience